compared 18 mo of treatment with teriparatide 20 mcg daily and raloxifene 60 mg daily to teriparatide alone in 77 postmenopausal women with osteoporosis who had already been taking raloxifene for at least 18 mo, and found that although BMD increases were numerically greater in the combination therapy group than the teriparatide alone group at the LS (9.2% vs 8.1%), TH (2.8% vs 1.8%), and FN (3.8% vs 2.2%) at 18 mo, these differences were not significant.12 This evidence concerns the gene FN1 and osteoporosis.